Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a phase II multicenter study by the Kamigata Breast Cancer Study Group

Tsuyuki, Shigeru; Senda, Noriko; Kanng, Yookija; Yamaguchi, Ayane; Yoshibayashi, Hiroshi; Kikawa, Yuichiro; Katakami, Nobuyuki; Kato, Hironori; Hashimoto, Takashi; Okuno, Toshitaka; Yamauchi, Akira; Inamoto, Takashi

doi:10.1007/s10549-016-3977-7

Cited by 63 publications

(75 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The gloved hand was compressed using gloves a size smaller. Less neuropathy was seen in the gloved versus the ungloved hand [28]. Compression therapy pursues the same approach as hypothermia by reducing blood flow in cold tissue as the fingertips of the glove-protected hand had a significant lower temperature than the ungloved hand.…”

Section: Prevention Of Cipnmentioning

confidence: 99%

Prevention and Management of Chemotherapy-Induced Polyneuropathy

et al. 2019

View full text Add to dashboard Cite

Chemotherapy-induced peripheral neurotoxicity (CIPN) is a severe and common side effect caused by a variety of antineoplastic agents. Approximately 30–40% of patients treated with agents such as taxanes, vinca alkaloids, or platinum derivatives will develop CIPN. CIPN presents predominantly as a sensory axonal neuro(no)pathy with occasional motor and autonomic dysfunction exhibiting considerable variability of clinical symptoms ranging from mild tingling sensation to severe neuropathic pain. Typical symptoms include numbness (“minus symptom”), weakness, and abnormal gait as well as paresthesia and pain (“positive symptoms”). As CIPN symptoms potentially lead to long-term morbidity and can even aggravate after cessation of therapy, patients’ quality of life can be tremendously affected. In view of improved breast cancer survival outcomes, the late effects of CIPN are an unmet need in these patients. Therefore, early detection and assessment of first symptoms is important to effectively prevent severe CIPN. Therapeutic options for patients with CIPN are still limited, and pharmacological treatment focuses primarily on reduction or relief of neuropathic pain. CIPN is usually acutely managed by dose reduction or discontinuation of causative chemotherapy, potentially compromising treatment outcome. Currently, there is no causative proven therapy for the prevention of CIPN.

show abstract

Section: Prevention Of Cipnmentioning

confidence: 99%

Prevention and Management of Chemotherapy-Induced Polyneuropathy

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Although several predictive factors of docetaxel-induced PN have been suggested, including pre-existing neuropathy (4), a body mass index ≥30 kg/m 2 (5), cumulative dose (3), and genetic variability (5), its underlying mechanisms remain largely unknown. The implementation of compression or cooling of limbs, or the administration of medications in order to prevent chemotherapy-induced PN has resulted in partial effectiveness (22,23). Our findings will be of greater help in clarifying the mechanisms underlying chemotherapyinduced PN than in identifying predictive factors, as the baseline values of the inflammation-based parameters were identical, regardless of the occurrence of PN.…”

Section: Figure 2 the Relationship Between The Occurrence Of Docetaxmentioning

confidence: 74%

The Relationship Between Peripheral Neuropathy Induced by Docetaxel and Systemic Inflammation-based Parameters in Patients with Breast Cancer

Yamanouchi

Kuba

Sakimura

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In a phase II self-controlled trial of compression therapy comparing the protected hand with the non-protected hand in the same patient, the incidence of CTCAE grade 2 or higher peripheral neuropathy was 21% on the affected hand and 76% on the control hand in breast cancer patients who received nab-paclitaxel treatment [26]. We assumed that the preventive effect of cryotherapy is as effective as compression therapy.…”

Section: Discussionmentioning

confidence: 99%

“…1 a Proportion of patients with clinically significant peripheral neuropathy (i.e., a decrease of 10% or more than 6 points compared with baseline in FACT-NTX score). b Baseline and posttreatment FACT-NTX scores Recently, preliminary reports showed the possibility of cryotherapy or compression therapy on affected hands and feet for the prevention of taxane-induced peripheral neuropathy and dermatologic toxicity [4,8,18,19,26]. In a self-controlled study evaluating the effect of frozen gloves/socks to prevent weekly paclitaxel related peripheral neuropathy in patients with breast cancer, there was a significant decrease in the occurrence of both objective and subjective signs of CIPN [8].…”

Section: Discussionmentioning

confidence: 99%

Cryotherapy for the prevention of weekly paclitaxel-induced peripheral adverse events in breast cancer patients

Shigematsu

Hirata

Nishina

et al. 2020

Support Care Cancer

View full text Add to dashboard Cite

Purpose This randomized phase II study was conducted to investigate the efficacy of cryotherapy in preventing peripheral neuropathy and dermatological adverse events in breast cancer patients treated with weekly paclitaxel. Methods Patients treated with 12 weekly doses of paclitaxel for breast cancer were randomized (1:1) into a cryotherapy or control group. The primary endpoint was the percentage of patients with a marked decrease in the Functional Assessment of Cancer Therapy-Neurotoxicity (FACT-NTX) score. The secondary endpoints were Patient Neurotoxicity Questionnaire (PNQ), Common Terminology Criteria for Adverse Event (CTCAE) for peripheral neuropathy, and FACT-Taxane score. Results Forty-four patients were randomly assigned to the cryotherapy (n = 22) or control groups (n = 22). The percentage of patients with a marked decrease in FACT-NTX scores was significantly lower in the cryotherapy group than in the control group (41 vs. 73%, p = 0.03). The incidence of CTCAE grade ≥ 2 sensory (p = 0.001) and motor peripheral neuropathy (p = 0.01), and PNQ grade D or higher for sensory peripheral neuropathy (p = 0.02), and decrease in the FACT-Taxane score (p = 0.02) were also significantly lower in the cryotherapy group than in the control group. There were no serious side effects associated with cryotherapy. Conclusion Cryotherapy is an effective approach for prevention of peripheral neuropathy and dermatological adverse events in breast cancer patients treated with weekly paclitaxel.

show abstract

Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a phase II multicenter study by the Kamigata Breast Cancer Study Group

Abstract: SG compression therapy is effective for reducing nab-PTX-induced peripheral neuropathy. The nab-PTX exposure to the peripheral nerve may be decreased because the SG decreases microvascular flow to the fingertip.

Cited by 63 publications

References 19 publications

Prevention and Management of Chemotherapy-Induced Polyneuropathy

Prevention and Management of Chemotherapy-Induced Polyneuropathy

The Relationship Between Peripheral Neuropathy Induced by Docetaxel and Systemic Inflammation-based Parameters in Patients with Breast Cancer

Cryotherapy for the prevention of weekly paclitaxel-induced peripheral adverse events in breast cancer patients

Contact Info

Product

Resources

About